Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

(MedPage Today) -- LOUISVILLE, Ky. -- Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small retrospective review suggested....